SIC Group, a Swiss industrial investor backed by Swiss KMU Partners, has invested in Sauter, Bachmann, a company engaged in developing and producing high-precision gears and gearboxes for Swiss and international clients in the aerospace
BGPartner announces the promotion of Fabiola Anthamatten (pictured left) to managing associate and Thomas Gysin (pictured right) to senior associate. Both have been an integral part of the BGPartner team for several years.
Essential Pharma, a portfolio company of Gyrus Capital, has acquired on December 8, 2021, the worldwide rights – except for the USA and India – to iopidine for the adjunctive treatment of glaucoma, and methergine for treating post-partum hemorrhage
SIG Combibloc, a leading systems and solutions provider for aseptic carton packaging, has entered into an agreement to acquire Pactiv Evergreen’s Asia Pacific
Baker McKenzie advised Chord Therapeutics (Chord) and its shareholders on the sale of all the shares in Chord to Merck KGaA (Merck). The acquisition is subject to regulatory clearances. This strategic acquisition will enable Merck
The OLX Group, classifieds business of Prosus, a global consumer internet group and one of the largest technology investors in the world, sold its investment in Encuentra24.com, a general classifieds marketplace in five key
Juliane Hogrefe becomes a partner at BGPartner. Juliane Hogrefe started as a junior associate at BGPartner in 2012. She is now a partner at the age of 36. During her career, Juliane Hogrefe not only developed into
Bär & Karrer announces the election of Susanne Schreiber (pictured) as senior partner of the firm. Schreiber will take over the position from Daniel Hochstrasser who served Bär & Karrer the last ten
Baker McKenzie advised Galenica Group (Galenica) on the sale and leaseback of the property at its headquarters in Berne to a Credit Suisse Asset Management real estate fund for around CHF 40 million. ADVISORING TEAM Baker
On December 15, 2021, Homburger successfully enforced Novartis’ deferasirox patents before the Swiss Federal Patent Court. The Court handed down a preliminary injunction judgment prohibiting Mepha Pharma from marketing a generic version of Novartis’ drug Jadenu® in
